Once a cancer therapy is approved and on the market, regulatory bodies continue to monitor its safety and efficacy through post-market surveillance. This includes collecting and analyzing adverse event reports, conducting additional studies, and sometimes mandating Risk Evaluation and Mitigation Strategies (REMS). Post-market surveillance helps identify any long-term or rare side effects that may not have been evident during clinical trials.
